变更后： 名称：哈尔滨三联威凯洱合成生物科技有限公司 除名称变更外，哈尔滨三联威凯洱合成生物科技有限公司《营业执照》的其 他登记事项均保持不变。 证券代码：002900 证券简称：哈三联 公告编号：2026-008 哈尔滨三联药业股份有限公司 关于全资子公司变更名称并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司收到全资子公司哈尔滨三联威凯洱合成生物 科技有限公司的通知，其对名称进行了变更，并已完成工商变更登记手续，取得 了哈尔滨新区管理委员会行政审批局换发的《营业执照》。具体变更情况如下： 变更前： 名称：哈尔滨裕诚生物科技有限公司 备查资料 1、哈尔滨三联威凯洱合成生物科技有限公司营业执照。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2026 年 3 月 27 日 ...

变更前： 许可项目：药品生产；药品批发；药品委托生产；兽药生产；兽药经营；检 验检测服务。一般项目：医用包装材料制造；基础化学原料制造（不含危险化学 品等许可类化学品的制造）；非居住房地产租赁；租赁服务（不含许可类租赁服 务）；化工产品生产（不含许可类化工产品）；化工产品销售（不含许可类化工产 品）；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；第一 类医疗器械生产；第一类医疗器械销售。（依法须经批准的项目，经相关部门批 准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 变更后： 证券代码：002900 证券简称：哈三联 公告编号：2026-007 哈尔滨三联药业股份有限公司 关于全资子公司变更经营范围并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司收到全资子公司兰西哈三联制药有限公司的 通知，其对经营范围进行了变更，并已完成工商变更登记手续，取得了兰西县市 场监督管理局换发的《营业执照》。具体变更情况如下： 除经营范围变更外，兰西哈三联制药有限公司《营业执照》的其他登记事项 ...

Group 1 - The company received a government subsidy of 6 million yuan, which accounts for 10.23% of the latest audited net profit attributable to shareholders [1] - The subsidy is classified as a revenue-related government grant, which is defined as grants not related to assets [1] - The subsidy is expected to positively impact the company's operating performance, with an anticipated increase in total profit of 6 million yuan for the year 2026 [2] Group 2 - The company has confirmed the receipt of the subsidy as of the announcement date [1] - Relevant documents regarding the subsidy include government approval documents and payment receipts [4]

Group 1 - The company’s wholly-owned subsidiary, Lanxi Hasi Pharmaceutical Co., Ltd., received a government subsidy of 6 million yuan, which accounts for 10.23% of the company's most recent audited net profit attributable to shareholders [1][2] - The subsidy is classified as a revenue-related government grant, which is expected to positively impact the company's operating performance by increasing the total profit for the year 2026 by 6 million yuan [2] Group 2 - The company assures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1] - Relevant documents regarding the subsidy, including government approval documents and payment receipts, will be kept on file for reference [4]

Group 1 - The company announced that its wholly-owned subsidiary, Lanxi Hasan Pharmaceutical, received a government subsidy of 6 million yuan related to revenue, which accounts for 10.23% of the company's most recent audited net profit attributable to shareholders [2] - The expected increase in total profit for the year 2026 is projected to be 6 million yuan [2]

Group 1 - The company, 哈三联, reported that as of February 13, 2026, the number of shareholders is 35,574 [2]

Core Viewpoint - Haisan Pharmaceutical (002900.SZ) announced that its wholly-owned subsidiary, Lanxi Haisan Pharmaceutical Co., Ltd., received a government subsidy of 6 million yuan, which accounts for 10.23% of the company's most recent audited net profit attributable to shareholders [1] Group 1 - The government subsidy is related to revenue and has been fully received by Lanxi Pharmaceutical as of the announcement date [1]

二、补助的类型及其对上市公司的影响 1、补助的类型 根据《企业会计准则第 16 号——政府补助》的规定，与资产相关的政府补 助，是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益 相关的政府补助，是指除与资产相关的政府补助之外的政府补助。上述政府补助 确认与收益相关的政府补助为 600 万元。 证券代码：002900 证券简称：哈三联 公告编号：2026-006 哈尔滨三联药业股份有限公司 关于全资子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、获得补助的基本情况 哈尔滨三联药业股份有限公司（以下简称"公司"）全资子公司兰西哈三联制 药有限公司（以下简称"兰西制药"）于 2026 年 2 月 13 日收到政府补助 600 万元， 占公司最近一期经审计归属于上市公司股东净利润的比例为 10.23%。该笔补助 系与收益相关的政府补助。截至本公告披露日，兰西制药已实际收到前述补助款 项。 3、风险提示和其他说明 上述政府补助最终会计处理及对公司相关财务数据的影响最终以会计师事 务所年度审计结果为准，敬请投资者注意投资风险 ...

Core Viewpoint - Haisan Pharmaceutical (002900.SZ) announced that its wholly-owned subsidiary, Lanxi Haisan Pharmaceutical Co., Ltd., received a government subsidy of 6 million yuan, which accounts for 10.23% of the company's most recent audited net profit attributable to shareholders [1] Group 1 - The government subsidy is related to revenue and has been fully received by Lanxi Pharmaceutical as of the announcement date [1]

Core Insights - The PDRN skincare market is projected to grow 27 times from 14.59 million yuan to 401 million yuan between 2023 and 2025, transitioning from a niche medical beauty category to a mainstream skincare staple [1][20][22] - The growth is driven by innovative product forms addressing consumer trust issues and urgent skincare needs, with domestic brands outperforming Korean brands, exemplified by Zhenweiya capturing a 33.9% market share compared to 1.6% for brands like Lijulan [1][12][11] Market Dynamics - Douyin accounts for 77.5% of sales, serving as a primary growth engine, while Tmall caters to higher-priced products and repeat purchases [2][27] - The market is shifting from oligopoly to full competition, with the CR3 dropping by 26.7%, indicating a more fragmented landscape [2][32] - The 300-600 yuan price range is identified as a high-growth area, with Zhenweiya dominating, while products under 100 yuan face intense competition [2][35] Product Trends - The next-generation product forms, particularly the "next-throw" format, have seen a staggering growth rate of 13,888%, with facial serums being the core category [2][12] - PDRN is increasingly competing in the light medical beauty and high-efficacy segments, targeting users lost by major brands [2][12] Industry Challenges - There is a significant mismatch between supply and demand, with supply-side focusing on high-end concepts while demand-side prioritizes practical experiences [2][11] - A trust crisis is emerging due to high concentrations leading to negative user experiences, with satisfaction for "heavy feel" dropping to -86% [2][12] Future Outlook - The PDRN industry is expected to enter a phase of differentiation and reshuffling, with a focus on practical applications over grand narratives [3][11] - Brands must optimize user experience, build trust, and develop proprietary technologies to succeed in the evolving market landscape [3][12][11]